Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026
Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026
Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Fineline Cube Jan 23, 2026
Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Fineline Cube Jan 26, 2026
Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Fineline Cube Jan 26, 2026
Company Deals

MeiraGTx Grants Eli Lilly Worldwide Rights to AAV‑AIPL1 Gene Therapy for LCA4

Fineline Cube Nov 11, 2025

MeiraGTx Holdings plc (NASDAQ: MGTX) announced a strategic ophthalmology collaboration with Eli Lilly and Company...

Company Drug

Innovent Biologics & Sanegene Bio USA Report First‑in‑Human Success for IBI3016 siRNA Hypertension Therapy

Fineline Cube Nov 11, 2025

Innovent Biologics, Inc. (HKG: 1801) and Sanegene Bio USA Inc. announced today the first‑in‑human (FIH)...

Company Drug

Hangzhou Bio‑Sincerity Secures NMPA Approval for BIOS‑0625 Tablet – First‑in‑Class Ulcerative Colitis Therapy

Fineline Cube Nov 11, 2025

Hangzhou Bio‑Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS‑0625 tablet, a Class 1 small‑molecule...

Company Deals

CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines

Fineline Cube Nov 11, 2025

CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co.,...

Company Deals

Eisai China and Beckman Coulter Launch Alzheimer’s Blood‑Test Collaboration in Mainland China

Fineline Cube Nov 10, 2025

Eisai China Holdings (TYO: 4523) and Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. today signed...

Company Drug

Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial

Fineline Cube Nov 10, 2025

Gilead Sciences Inc. (NASDAQ: GILD) today disclosed that the Phase III ASCENT‑07 study, which compared Trodelvy...

Company Deals

Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance

Fineline Cube Nov 10, 2025

Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...

Company Deals

SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases

Fineline Cube Nov 10, 2025

SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and...

Company Deals

DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform

Fineline Cube Nov 10, 2025

Nantong DeliNova Therapeutics Co., Ltd. announced today the successful closing of a seed‑stage financing round...

Company Deals

Organon Acquires JADA System from Laborie for USD 465 Million

Fineline Cube Nov 10, 2025

Organon Inc. (NYSE: OGN) announced today that it has entered into an agreement with Laborie...

Company Deals Digital

HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration

Fineline Cube Nov 10, 2025

HBM Holdings Limited (HKG: 2142) and Evinova, an independent health‑tech arm of the AstraZeneca Group,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Announces HRS‑2430 Injection Approval for Clinical Trials

Fineline Cube Nov 10, 2025

China‑listed Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous...

Others

National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)

Fineline Cube Nov 10, 2025

The National Health Commission (NHC) announced on 7 November 2025 a “Negative Behavior List for Medical Staff...

Company Deals

Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal

Fineline Cube Nov 10, 2025

Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...

Company Deals

Aureka Biotechnologies Closes Multi‑Million‑Dollar Series A – Generative Antibody Platform Gains 5Y Capital & Qiming Backing

Fineline Cube Nov 10, 2025

Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of...

Company Deals

Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion

Fineline Cube Nov 8, 2025

China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s...

Company Deals

Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030

Fineline Cube Nov 8, 2025

During the 8th China International Import Expo (CIIE), the Shanghai Medical Association (SMA) and Boehringer Ingelheim...

Company Deals Hospital

Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative

Fineline Cube Nov 8, 2025

Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...

Company

Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows

Fineline Cube Nov 8, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third‑quarter 2025 financial results, reporting total...

Company Deals

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Fineline Cube Nov 8, 2025

In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...

Posts pagination

1 … 29 30 31 … 613

Recent updates

  • Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up
  • Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study
  • Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing
  • HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance
  • Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Company Drug

Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing

Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.